VKTX Viking Therapeutics, Inc.

NASDAQ
$33.19

Viking Therapeutics, Inc. (VKTX) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $1.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.0% since its last earnings release on July 29, 2026.

Viking Therapeutics Beat Consensus Estimates
Wednesday, July 29, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 28
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($1.00)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $33.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.

Sector

Healthcare

Industry

Biotechnology